NCT07524374

SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy

The Efficacy, Safety and Feasibility of SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of Esophageal Squamous Cell Carcinoma After Immunotherapy

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: Zhigang Li · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a single-arm, exploratory clinical trial aimed at evaluating the efficacy and safety of SHR-1701 in combination with liposomal irinotecan (II) in patients with esophageal squamous cell carcinoma who have received prior immunotherapy. Eligible patients with esophageal cancer will be treated with SHR-1701 in combination with liposomal irinotecan (II).

Conditions

• ESCC

Interventions

Type	Name	Description
DRUG	SHR-1701+ liposomal irinotecan (II)	SHR-1701 in combination with Irinotecan Liposome (II) is administered on Day 1 of each 3-week treatment cycle until disease progression, intolerable toxicity, withdrawal of consent, or a decision by the investigator to discontinue treatment, or until the maximum treatment duration of 2 years has been reached, whichever occurs first.

Timeline

• Start date: 2026-03-15
• Primary completion: 2027-09-30
• Completion: 2028-03-30
• First posted: 2026-04-13
• Last updated: 2026-04-13

Locations

1 site across 1 country: China